Albumin-based delivery systems: Recent advances, challenges, and opportunities
Gespeichert in:
| Titel: | Albumin-based delivery systems: Recent advances, challenges, and opportunities |
|---|---|
| Autoren: | Murphy, Gillian, Brayden, David J., Cheung, David L., Liew, Aaron, Fitzgerald, Michael, Pandit, Abhay |
| Weitere Verfasser: | University of Galway Research Repository |
| Quelle: | Journal of Controlled Release. 380:375-395 |
| Verlagsinformationen: | Elsevier BV, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | Biomaterials, Drug Carriers, Drug Delivery Systems, Computational modelling, Albumins, Albumin, Commercialization, Humans, Animals, Nanoparticles, Albumin conjugates, Albumin nanoparticles, Medical device |
| Beschreibung: | Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems. |
| Publikationsart: | Article |
| Dateibeschreibung: | application/octet-stream |
| Sprache: | English |
| ISSN: | 0168-3659 |
| DOI: | 10.1016/j.jconrel.2025.01.035 |
| DOI: | 10.13025/29398 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/39842723 |
| Rights: | CC BY NC CC BY NC ND |
| Dokumentencode: | edsair.doi.dedup.....f28a25a0007267aaa9aacbaa2e179590 |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems. |
|---|---|
| ISSN: | 01683659 |
| DOI: | 10.1016/j.jconrel.2025.01.035 |